New drug cocktail before transplant shows promise for tough leukemia

NCT ID NCT06483906

First seen Mar 05, 2026 · Last updated May 02, 2026 · Updated 9 times

Summary

This study tests a new combination of three drugs (venetoclax, azacitidine, and homoharringtonine) followed by a stem cell transplant for people with intermediate or high-risk acute myeloid leukemia (AML). About 56 adults aged 18-55 who have not had prior leukemia treatment will receive up to four cycles of the drug combo. If tests show the leukemia is gone, they will get a donor stem cell transplant. The goal is to see if this approach improves survival and reduces the chance of the cancer coming back.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ACUTE MYELOID LEUKEMIA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Shanghai General hospital,Shanghai Jiao Tong University School of Medicine

    RECRUITING

    Shanghai, Shanghai Municipality, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.